Free Trial
NASDAQ:FBLG

FibroBiologics Q3 2025 Earnings Report

FibroBiologics logo
$1.16 -0.08 (-6.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.15 -0.01 (-0.86%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics EPS Results

Actual EPS
-$2.60
Consensus EPS
-$2.00
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Friday, October 31, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

FibroBiologics' Q2 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules

FibroBiologics Earnings Headlines

FibroBiologics CEO Issues Letter to Shareholders
FibroBiologics (NASDAQ:FBLG) Receives Hold Rating from Maxim Group
Batten down the hatches – Project Tengu is coming
Starting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most disruptive company in the world." It's not SpaceX or OpenAI. In fact, its annualized revenues have already surpassed both of these firms. And this 60-year Wall Street legend believes it's gearing up for a watershed product launch that could send its sales soaring even higher starting June 16.tc pixel
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile